-
朗格汉斯细胞组织细胞增生症(Langerhans cell histiocytosis,LCH)是一种未成熟树突状细胞异常增生导致的肿瘤性疾病[1]。其发病机制复杂,临床表现多样,既可累及单系统,亦可累及多系统,临床诊断面临较大的挑战。笔者报道了1例经术后组织病理学检查结果证实的LCH病例,对其影像资料进行回顾性分析,旨在提高临床医师对该病的认识。
多系统朗格汉斯细胞组织细胞增生症 18F-FDG PET/CT 显像1例
Multi-system Langerhans cell histiocytosis in 18F-FDG PET/CT imaging: a case report
-
摘要: 朗格汉斯细胞组织细胞增生症(LCH)是一种罕见的未成熟树突状细胞异常增生的肿瘤性疾病,其组织病理学检查为诊断的“金标准”。笔者报道了1例青少年多系统LCH的CT、MRI及18F-氟脱氧葡萄糖(FDG) PET/CT显像病例,从临床、组织病理学、影像、治疗等方面分析了该病的特点,并通过文献复习加深了对该病的认识,为该病的诊断提供更多参考。Abstract: Langerhans cell histiocytosis (LCH) is a rare neoplastic disease with abnormal proliferation of immature dendritic cells, and histopathological examination is the "gold standard" for its diagnosis. The author reports a case of multisystem LCH in an adolescent with CT, MRI, and 18F-fluorodeoxyglucose(FDG) PET/CT imaging, and analyzes the characteristics of the disease from the clinical, histopathological, imaging, and therapeutic perspectives, and deepens the understanding of the disease by reviewing the literature to provide more references for the diagnosis of the disease.
-
Key words:
-
-
[1] 中华医学会病理学分会儿科病理学组, 福棠儿童医学发展研究中心病理专业委员会, 中国抗癌协会小儿肿瘤专业委员会病理学组. 朗格汉斯细胞组织细胞增生症病理诊断专家共识[J]. 中华病理学杂志, 2022, 51(8): 696−700. DOI: 10.3760/cma.j.cn112151-20220317-00194.
Expert Group of Pediatrics of Chinese Society of Pathology, Expert Group of Pathology Committee of Futang Research Center of Pediatric Development, Expert Group of Pathology of Chinese Children Cancer Group. Consensus on the diagnosis of Langerhans cell histiocytosis[J]. Chin J Pathol, 2022, 51(8): 696−700. DOI: 10.3760/cma.j.cn112151-20220317-00194.[2] Zinn DJ, Chakraborty R, Allen CE. Langerhans cell histiocytosis: emerging insights and clinical implications[J]. Oncology (Williston Park), 2016, 30(2): 122−132, 139. [3] Salotti JA, Nanduri V, Pearce MS, et al. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland[J]. Arch Dis Child, 2009, 94(5): 376−380. DOI: 10.1136/adc.2008.144527. [4] Kobayashi M, Tojo A. Langerhans cell histiocytosis in adults: advances in pathophysiology and treatment[J]. Cancer Sci, 2018, 109(12): 3707−3713. DOI: 10.1111/cas.13817. [5] Krooks J, Minkov M, Weatherall AG. Langerhans cell histiocytosis in children: history, classification, pathobiology, clinical manifestations, and prognosis[J]. J Am Acad Dermatol, 2018, 78(6): 1035−1044. DOI: 10.1016/j.jaad.2017.05.059. [6] Kilpatrick SE, Wenger DE, Gilchrist GS, et al. Langerhans' cell histiocytosis (histiocytosis X) of bone a clinicopathologic analysis of 263 pediatric and adult cases[J]. Cancer, 1995, 76(12): 2471−2484. DOI: 10.1002/1097-0142(19951215)76:12< 2471::aid-cncr2820761211>3.0.co;2-z. [7] Haupt R, Minkov M, Astigarraga I, et al. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years[J]. Pediatr Blood Cancer, 2013, 60(2): 175−184. DOI: 10.1002/pbc.24367. [8] 董楚宁, 姜阳, 李娴, 等. 18F-FDG PET/CT对朗格汉斯细胞组织细胞增生症的价值[J]. 临床放射学杂志, 2020, 39(11): 2297−2303. DOI: 10.13437/j.cnki.jcr.2020.11.034.
Dong CN, Jiang Y, Li X, et al. Role of 18F-FDG PET/CT in management of Langerhans cell histiocytosis[J]. J Clin Radiol, 2020, 39(11): 2297−2303. DOI: 10.13437/j.cnki.jcr.2020.11.034.[9] 张彦彦, 张卫方. 成人脊柱朗格汉斯细胞组织细胞增生症的18F-FDG PET/CT表现[J]. 中国医学影像技术, 2019, 35(1): 134−137. DOI: 10.13929/j.1003-3289.201805081.
Zhang YY, Zhang WF. 18F-FDG PET/CT manifestations of Langerhans cell histiocytosis in adult spine[J]. Chin J Med Imaging Technol, 2019, 35(1): 134−137. DOI: 10.13929/j.1003-3289.201805081.[10] 叶黛西, 陈绍亮, 耿承军. PET/CT显像诊断成人多发骨骼朗格汉斯细胞组织细胞增生症1例[J]. 中国介入影像与治疗学, 2020, 17(9): 575−576. DOI: 10.13929/j.issn.1672-8475.2020.09.016.
Ye DX, Chen SL, Geng CJ. PET/CT diagnosis of Langerhans cell histiocytosis in bones: case report[J]. Chin J Interv Imaging Ther, 2020, 17(9): 575−576. DOI: 10.13929/j.issn.1672-8475.2020.09.016.[11] Yang Y, Wang D, Cui L, et al. Effectiveness and safety of dabrafenib in the treatment of 20 Chinese children with BRAFV600E-mutated Langerhans cell histiocytosis[J]. Cancer Res Treat, 2021, 53(1): 261−269. DOI: 10.4143/crt.2020.769. [12] Abla O. Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease[J]. Hematology Am Soc Hematol Educ Program, 2023, 2023(1): 386−395. DOI: 10.1182/hematology.2023000439.